Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2023
Foghorn Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-39634 47-5271393
(State or other jurisdiction of incorporation) 
File Number)
 (IRS Employer Identification No.)
500 Technology Square, Ste 700
(Address of principal executive offices)(Zip Code)
(Registrant’s telephone number, including area code): (617) 586-3100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:  
Title of each class 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share FHTX The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 8.01     Other Information

On August 8, 2023, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing that Samuel Agresta, M.D., will step down from his position as Chief Medical Officer of the Company effective as of September 11, 2023. Following his resignation, Dr. Agresta will serve as a consultant to the Company through early January 2024.

The Company also announced that Alfonso Quintás-Cardama, M.D., has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 11, 2023.

Dr. Quintás-Cardama previously served as Chief Medical Officer of TCR2 Therapeutics Inc., a position he held since 2017. Prior to that, he was the Clinical Development Head of the Cell & Gene Therapies Unit at GlaxoSmithKline PLC in 2017. Between 2014 and 2016, Dr. Quintás-Cardama served as Global Clinical Leader, Cell & Gene Therapy, at Novartis AG and was an Assistant Professor in the Department of Leukemia at the University of Texas, MD Anderson Cancer Center from 2009 to 2014. Dr. Quintás-Cardama received his M.D. from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine of the Albert Einstein College of Medicine, and a hematology and oncology fellowship and a leukemia fellowship at the University of Texas, MD Anderson Cancer Center.

A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1    Press release issued on August 8, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Allan Reine
 Allan Reine, M.D.
 Chief Financial Officer
Date: August 8, 2023

Exhibit 99.1
Foghorn Therapeutics Announces Chief Medical Officer Succession
CAMBRIDGE, Mass. -- (GLOBE NEWSWIRE) -- August 8, 2023 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced that Alfonso Quintás-Cardama, M.D., will join the company as Chief Medical Officer, on September 11, 2023. Foghorn’s current Chief Medical Officer, Sam Agresta, M.D., will simultaneously retire from the company on September 11, 2023, and will provide consulting services through early January 2024.

“I want to thank Sam for his leadership and many contributions to Foghorn over the past four years. He joined the company at a critical time and built our clinical team which advanced our first programs to the clinic,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Sam has been a valued partner to me and the entire organization, and his unwavering focus on our mission to serve patients has been inspiring not just to me, but to all of us.”
Gottschalk continued, “We are excited to welcome Alfonso to the Foghorn team. Alfonso’s experience and expertise in oncology and as a leukemia expert will be integral to our plans as we continue to advance our pipeline and develop medicines for patients.”
Dr. Quintás-Cardama most recently was the Chief Medical Officer at TCR2 since 2017, where he led the development of the company’s cell therapy platform. Dr. Quintás-Cardama’s prior experience includes a role as the head of clinical development for cell therapies at GSK, where he was instrumental in building GSK’s cell therapies unit, and as the global clinical leader at Novartis from 2014 to 2016, where he led the development of tisagenlecleucel (Kymriah™, CTL019), the first FDA-approved CAR-T cell therapy. Dr. Quintás-Cardama was previously a faculty member of the Department of Leukemia at MD Anderson Cancer Center from 2009 to 2014, where he developed multiple FDA-approved targeted agents for the treatment of myeloid malignancies.
“As a leader in understanding and drugging chromatin biology, Foghorn is uniquely positioned to develop the next class of cancer medicines,” said Dr. Quintás-Cardama. “I am excited to join Foghorn given the company’s broad pipeline coupled with a platform that has enabled the drugging of some of the most compelling targets in cancer. I am looking forward to being part of the Foghorn journey as the company continues to address unmet needs in cancer and brings potential therapies to people who need it the most.”
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at

www.foghorntx.com for more information on the company, and follow us on X (formally Twitter) and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, including its Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML patients, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Ben Strain, Foghorn Therapeutics Inc. (Media and Investors)
Karin Hellsvik, Foghorn Therapeutics Inc. (Media)